// App-Quantinova.ai

: A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Elizabeth R. Plimack

  • Hendrik-Tobias Arkenau

  • Eric Jonasch

  • Daniel Yick Chin Heng

  • Thomas Powles

  • Melanie M. Frigault

  • Edwin Clark

  • Amir Handzel

  • Humphrey Athelstan Gardner

  • Shethah Morgan

  • Laurence Albiges

  • Sumanta K. Pal

Medical Centers

  • Dana-Farber/Harvard Cancer Center, Boston, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • Sarah Cannon Research Institute, London, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • AstraZeneca, Boston, MA

  • AstraZeneca, Waltham, Boston, MA

  • AstraZeneca, Waltham, MA

  • AstraZeneca, Macclesfield, United Kingdom

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • City of Hope, Duarte, CA

Locations

  • United States

  • United Kingdom

  • Canada

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Savolitinib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • NA

Study Id's

  • NCT02127710

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved